Abstract
For patients with clinical suspicion of prostate cancer, liquid biomarkers are the next best test because of their accessibility, objectiveness, and noninvasive nature. A highly sensitive cutoff for these biomarkers should be used to triage patients before use of magnetic resonance imaging.
